RetinaCME

This activity is expired and is no longer available for CME credit.

LECTURECME

Neovascular AMD: Navigating Advancing Science in Anti-VEGF Therapy

Author(s)/Faculty: Carmen A. Puliafito, MD, MBA; Michael W. Stewart, MD; Peter K. Kaiser, MD; Philip J. Rosenfeld, MD, PhD; Srinivas R. Sadda, MD
Release Date: 12/31/2012Expiration Date: 12/30/2013
Credit Type: CMENumber of Credits: 0
Content Type: Provider:
The use of the VEGF inhibitors ranibizumab and bevacizumab has revolutionized the management of age-related macular degeneration, offering more directed approaches to therapy that avoid the damage to peripheral tissue associated with laser treatment while achieving a reversal of vision loss for many patients. The newer anti-VEGF agent aflibercept has been shown to achieve resolution of vascular leakage in patients who do not respond to initial therapy, and may be effective at lower dosing frequency, making treatment less onerous for patients and clinicians. These properties may also be beneficial to patients with other retinal disorders, including diabetic macular edema and retinal vein occlusions. This program will review treatment options for treating wet age-related macular degeneration, including complicated cases, and explore other potential applications...